Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
LLYEli Lilly & Co. -0.72%363.001.1%$1183.94m
JNJJohnson & Johnson -0.13%176.990.7%$1095.82m
MRKMerck & Co., Inc. 0.04%107.500.7%$995.24m
PFEPfizer Inc. -0.10%49.150.9%$980.13m
ABBVAbbVie, Inc. -0.25%159.211.9%$904.50m
BMYBristol-Myers Squibb Co. -0.16%79.141.1%$749.90m
AZNAstraZeneca Plc 0.35%66.401.0%$361.42m
IDXXIDEXX Laboratories, Inc. 0.00%411.363.9%$222.64m
GSKGSK Plc -0.09%33.960.3%$201.84m
HZNPHorizon Therapeutics Plc 0.00%78.285.4%$201.37m
NVSNovartis AG -0.03%87.760.2%$189.98m
CTLTCatalent, Inc. 0.05%41.411.9%$163.88m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%212.728.0%$159.13m
NVONovo Nordisk A/S 1.10%120.150.1%$157.34m
SNYSanofi 1.06%45.870.2%$123.02m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.